Full FDA approval of Eisai and Biogen’s Alzheimer’s disease therapy Leqembi may have unlocked the door to a broader rollout of the drug and potentially blockbuster sales,
The Centers for Medicare and Medicaid Services (CMS) in the US has provided more details about the controversial plan to require participation in a patient registry as a c
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.